Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients
Trauma remains the leading cause of death and disability for Americans age 1-44. Trauma can cause internal bleeding, and this bleeding is often hard to detect without sophisticate tests that take time to complete and analyze.
In addition, internal bleeding, including bleeding into the lung and chest cavity, as well as other blood loss, happens in many critically ill patients. For example, for hemorrhage, it is very difficult to detect active hemorrhage and to determine optimal rates of fluid and blood resuscitation.
Diffuse optical spectroscopy has the potential to accurately assess adequacy of tissue perfusion, oxygenation, tissue oxygen extraction, and cytochrome oxidation states that may be critical to optimal treatment, end- organ preservation, and survival.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients|
- The ability to noninvasively diagnose conditions in the intensive care unit, or in battlefield conditions. [ Time Frame: 5 to 60 seconds ] [ Designated as safety issue: No ]
|Study Start Date:||March 2007|
|Study Completion Date:||April 2011|
|Primary Completion Date:||April 2011 (Final data collection date for primary outcome measure)|
The research' want to monitor tissue perfusion and indicators of tissue damage and viability in critically ill patients by using DOS.
Non-invasive Optical Techniques DOS,near-infrared diffuse optical spectroscopy (NIR-DOS.
NIR-DOS provides functional physiologic tissue/organ information without ionizing radiation and without withdrawing any blood, in a cost-effective and rapid manner. The application of frequency-domain photon migration analysis (FDPM) to NIRS allows independent measurements of tissue absorption and scattering properties at depths of 1 cm or more below the skin surface.
Such capabilities will improve early diagnosis, detection, optimization of therapy, assessment of adequacy of resuscitation, and alteration in management plans for all of these critical conditions.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00581295
|United States, California|
|Beckman Laser Institute,University of California, Irvine|
|Irvine, California, United States, 92612|
|Trauma/Critical Care Units, UCI Medical Center|
|Orange, California, United States, 92686|
|Principal Investigator:||Michael E Lekawa, M.D||Beckman Laser Institute|